- Home
- BME vs VNDA Comparison
BME vs VNDA Comparison
Compare BME & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BME | VNDA |
|---|---|---|
| Founded | 2005 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 545.3M | 474.0M |
| IPO Year | N/A | 2006 |
Fundamental Metrics
Financial Performance| Metric | BME | VNDA |
|---|---|---|
| Price | $41.95 | $7.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $13.63 |
| AVG Volume (30 Days) | 34.0K | ★ 1.1M |
| Earning Date | 01-01-0001 | 02-11-2026 |
| Dividend Yield | ★ 6.26% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.44 | N/A |
| Revenue | N/A | ★ $212,074,000.00 |
| Revenue This Year | N/A | $12.01 |
| Revenue Next Year | N/A | $24.28 |
| P/E Ratio | $28.37 | ★ N/A |
| Revenue Growth | N/A | ★ 11.12 |
| 52 Week Low | $35.53 | $3.81 |
| 52 Week High | $43.20 | $9.60 |
Technical Indicators
Market Signals| Indicator | BME | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 54.35 | 46.73 |
| Support Level | $41.59 | $7.37 |
| Resistance Level | $42.40 | $8.30 |
| Average True Range (ATR) | 0.54 | 0.42 |
| MACD | -0.05 | -0.10 |
| Stochastic Oscillator | 61.33 | 10.62 |
Price Performance
Historical ComparisonAbout BME Blackrock Health Sciences Trust
Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.